• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.

  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

CAR T Cell Assay Services

Designed to transform cell-based immunotherapies for solid tumors.

Chimeric Antigen Receptor (CAR) T cell therapy is a breakthrough in cancer treatment, employing engineered T cells equipped with CARs to target and destroy cancer cells. Despite its success in treating blood cancers, CAR T therapy for solid tumors encounters significant obstacles— including reduced infiltration/cytotoxicity of CAR-T cells, and tumor evasion through immunosuppressive tumor microenvironment or resistant cancer cells.

Unlike conventional cell-based assays, MIMETAS' 3D CAR T cell assay platform uniquely replicates the complex tumor microenvironment (TME), offering unparalleled insights into CAR T cell behavior, targeting precision, and patient-specific responses in solid tumors.

Model Details

An Accurate 3D Tumor Microenvironment

 

  • Perfused 3D Blood Vessels: Engineered to allow natural CAR T cell interaction and migration within the blood vessel, simulating vascular access to the tumor.
  • 3D ECM with Embedded Tumor Cells: Closely replicating native tissue for studying CAR T cell attraction, infiltration, and cytotoxic effects.
  • Unobstructed CAR T Cell Trafficking: Using PhaseGuide™ technology, CAR T cells move seamlessly from the bloodstream into the tumor.
  • Complex TME: Optional integration of cancer-associated fibroblasts (CAFs) and macrophages (CAMs) offers insight into the role of supporting cells in CAR T cell behavior.
  • Customizable Tumor Conditions: Adjustable ECM composition and supporting cells allow for tailored TME conditions to study CAR T cell migration, activation, and modulation.
  • Patient-Specific Modeling: Using primary tumor cells addresses patient-specific and target heterogeneity, enabling personalized immunotherapy research.


Speak With an Expert

Assays

CAR T Cell Trafficking to Tumor Tissue

Track CAR T cell movement and engagement in real-time

  • Starting in blood vessels and ending in target tissues, we quantify circulation through the blood vessel, activation of endothelium, extravasation, migration through the extracellular matrix, and killing of the target expressing tumor cells over time.
  • Real-time visualization also provides potential differences between target and non-target cell interactions. This provides critical information on the targeting accuracy and efficiency of various CAR T constructs.
  • Cytokine release provides insight into T cell-mediated killing and the influence of the tumor microenvironment.


CAR T cell migration towards non-target and target cells in presence of CXCL12

Solid Tumor Killing by CAR T Cells

Assess Tumor-Killing Potential

  • Evaluation of CAR T cell efficacy and effector-to-target ratios
  • Assessment of the efficacy of different CAR T variants.
  • Working with multiple donors provides insight in heterogeneity of tumors between patients;
  • Working with patient derived material we capture target heterogeneity within the tumor.


Tumor cell death upon CAR T treatment

Comparison and Ranking of CAR T Cell Constructs Based on Killing Efficacy

Our platform facilitates:

  • Directly compare and rank CAR T constructs based on their tumor-killing efficacy, including variations such as CD28 or 4-1BB co-stimulatory domains.
  • Combination therapy enhancing CAR T performance.
  • Study CAR T-associated toxicity and/or on-target off tumor toxicity to the blood vessel or other organ cells.

Tumor area response by construct type, detailing the higher efficacy observed with different co-stimulatory domains.

Why Choose MIMETAS for CAR T Cell Assays?

 

With an innovative platform designed to replicate complex TMEs, we offer unmatched CAR T cell assay services for solid tumor research. Here’s why researchers and developers turn to MIMETAS:

  • Realistic TME: Our 3D platform replicates solid tumor complexity, including blood vessels, for precise CAR T cell studies.
  • Flexible Assay Conditions: Tunable models replicate specific TMEs, including ECM, stromal cells, and tumor types.
  • Patient-Specific Insights: Use of patient-derived cells to study individual heterogeneity.
  • Comprehensive Evaluation: Our platform delivers data on target specificity and CAR T-associated toxicity to optimize CAR T constructs for solid tumors.

 

Speak With an Expert

Discover Other Oncology Applications

Download our latest whitepaper to uncover:

  • The urgent need for advanced, predictive models in cancer research.
  • Insights from six oncology applications of MIMETAS’ 3D tumor models.
  • Quantifiable results for informative decision making.
  • The impact of a strategic partnership with MIMETAS in accelerating the discovery of new cancer treatments.

 


Download the Whitepaper Explore our Oncology Services

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all